Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as JNJ-54175446 (capsule)
JNJ-54175446 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A: JNJ-54175446 | EXPERIMENTAL | Participants will receive a loading dose of JNJ-54175446, 600 milligram (mg) on Day 1 followed by JNJ-54175446, 150 mg once daily until Day 10. |
| Group B: Placebo + JNJ-54175446 | EXPERIMENTAL | Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10. |
| Group C: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo from Day 1 until Day 10. |
| Name | Type | Description |
|---|---|---|
| JNJ-54175446, 600 mg | DRUG | Participants will receive JNJ-54175446, 600 mg as an oral suspension. |
| JNJ-54175446, 150 mg | DRUG | Participants will receive JNJ-54175446, 150 mg as an oral suspension. |
| Placebo | OTHER | Matching placebo to JNJ-54175446 |
Inclusion Criteria: * Body mass index (BMI) must be between 18 and 32 kilogram per square meter (kg/m\^2) inclusive * Related to symptoms of depression: Participant must meet the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV or V diagnostic criteria for Major Depressive Disorder \[...
JNJ-54175446 is an investigational small molecule being studied for the treatment of major depressive disorder. It has been evaluated in a Phase 1 clinical trial in participants with major depressive disorder. It is not approved for any indication and remains in clinical development.
JNJ-54175446 targets P2RX7, the P2X7 receptor. It acts as an antagonist at this target. By blocking P2RX7, the drug is designed to modulate neuroinflammatory signaling, a mechanism being explored in major depressive disorder.
JNJ-54175446 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 trial of the drug in major depressive disorder.
JNJ-54175446 is in Phase 1 clinical development. It has completed one Phase 1 trial in major depressive disorder. The drug is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
JNJ-54175446 has been studied in one completed Phase 1 trial, NCT02902601, titled A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder. The trial enrolled 70 participants across Germany and the Netherlands and was randomized, double-blind, and placebo-controlled.
Yes, JNJ-54175446 and JNJ 54175446 refer to the same investigational drug. Other variations seen in study listings include JNJ-54175446 150 mg, JNJ-54175446 600 mg, and JNJ-54175446 (capsule), which describe dose strengths and the capsule formulation used in trials.